Agios Pharmaceuticals (NASDAQ:AGIO) Announces Earnings Results

Agios Pharmaceuticals (NASDAQ:AGIO) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04), FiscalAI reports. The business had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%.

Here are the key takeaways from Agios Pharmaceuticals’ conference call:

• Mitapivat revenue reached $44.7 million in Q2, including $40.9 million in the U.S., while AQVESME generated 442 cumulative prescriptions from REMS-certified physicians. Payer coverage for U.S. thalassemia patients reached approximately 75%.
• The FDA accepted mitapivat’s sickle cell disease supplemental application for priority review with a November 1, 2026 PDUFA date; Agios is preparing for a potential launch, though the indication is not expected to materially contribute to 2026 revenue.
• Thalassemia launch dynamics are shifting toward a broader non-transfusion-dependent population, which may lengthen treatment initiation to the expected 10–12 weeks. Management will evaluate six-month patient benefit and persistence in the second half and plans to stop reporting REMS prescription counts after Q3 in favor of revenue metrics.
• Agios expanded its rare hematology pipeline by licensing cevidoplenib, a selective oral Syk inhibitor for immune thrombocytopenia, and plans to advance AG-236 into a seamless Phase II/III polycythemia vera program in the second half of 2026.
• The company ended the quarter with approximately $1 billion in cash and marketable securities, but operating expenses increased as commercial investment expanded; full-year operating expenses are expected to remain roughly flat versus 2025 excluding the $25 million cevidoplenib upfront payment.

Agios Pharmaceuticals Price Performance

AGIO traded down $2.26 during trading hours on Thursday, reaching $32.75. The company’s stock had a trading volume of 3,134,451 shares, compared to its average volume of 1,054,030. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The stock has a market cap of $1.95 billion, a PE ratio of -4.52 and a beta of 0.54. The business’s 50-day moving average is $34.37 and its 200-day moving average is $30.86.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Truist Financial increased their price target on Agios Pharmaceuticals from $36.00 to $41.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. HC Wainwright boosted their price objective on Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a research note on Thursday. Bank of America upped their target price on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. JPMorgan Chase & Co. cut their target price on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a research note on Thursday, June 11th. Finally, The Goldman Sachs Group lifted their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, April 1st. Five research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $40.38.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter worth $25,000. NewEdge Advisors LLC acquired a new position in Agios Pharmaceuticals in the first quarter valued at about $40,000. Caitong International Asset Management Co. Ltd acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at about $49,000. Quantbot Technologies LP purchased a new position in Agios Pharmaceuticals during the third quarter worth about $79,000. Finally, Acadian Asset Management LLC purchased a new position in Agios Pharmaceuticals during the first quarter worth about $133,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.